EA202090003A1 - Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка - Google Patents

Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка

Info

Publication number
EA202090003A1
EA202090003A1 EA202090003A EA202090003A EA202090003A1 EA 202090003 A1 EA202090003 A1 EA 202090003A1 EA 202090003 A EA202090003 A EA 202090003A EA 202090003 A EA202090003 A EA 202090003A EA 202090003 A1 EA202090003 A1 EA 202090003A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biological activity
cell
binding
manifestates
binding molecules
Prior art date
Application number
EA202090003A
Other languages
English (en)
Inventor
Сесилия Анна Вильгельмина Гёин
Ринсе Клостер
Корнелис Адриан Де Крёйф
Паулус Йоханнес Таккен
Марк Тросби
Тон Логтенберг
Original Assignee
Мерус Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерус Н.В. filed Critical Мерус Н.В.
Publication of EA202090003A1 publication Critical patent/EA202090003A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В соответствии с изобретением предложены средства и способы ингибирования биологической активности клеток. В одном варианте реализации настоящего изобретения предложен способ ингибирования биологической активности в первой или второй клетке, опосредуемой связыванием двух мембранных белков, которые являются партнерами по связыванию друг для друга. Упомянутая биологическая активность ингибируется при контакте клеток с антителом или подобной антителу молекулой, способным связываться с каждым из упомянутых партнеров по связыванию, и данное связывание блокирует связывание двух партнеров по связыванию, тем самым ингибируя упомянутую биологическую активность.
EA202090003A 2017-07-06 2018-07-06 Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка EA202090003A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180064 2017-07-06
PCT/NL2018/050449 WO2019009726A1 (en) 2017-07-06 2018-07-06 BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

Publications (1)

Publication Number Publication Date
EA202090003A1 true EA202090003A1 (ru) 2020-06-18

Family

ID=59295094

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090003A EA202090003A1 (ru) 2017-07-06 2018-07-06 Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка

Country Status (14)

Country Link
US (2) US11667714B2 (ru)
EP (1) EP3649154A1 (ru)
JP (2) JP7438098B2 (ru)
KR (1) KR20200037791A (ru)
CN (1) CN111094347A (ru)
AU (1) AU2018296067B2 (ru)
BR (1) BR112020000209A8 (ru)
CA (1) CA3068929A1 (ru)
EA (1) EA202090003A1 (ru)
IL (1) IL271817A (ru)
PH (1) PH12020550011A1 (ru)
SG (1) SG11202000014UA (ru)
TW (1) TW201920264A (ru)
WO (1) WO2019009726A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
BR112020019795A2 (pt) * 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
MX2021004897A (es) * 2019-04-26 2021-06-18 I Mab Biopharma Us Ltd Anticuerpos pd-l1 humano.
CN114702587A (zh) 2019-05-09 2022-07-05 美勒斯公司 用于使蛋白质多聚化的变体结构域及其分离
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
CN113416249B (zh) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
KR20230135637A (ko) * 2021-01-28 2023-09-25 넥스트포인트 테라퓨틱스, 인코포레이티드 새로운 활성을 갖는 hhla2 결합제
EP4314061A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel multispecific antibodies
JP2024511589A (ja) * 2021-03-31 2024-03-14 メルス ナムローゼ フェンノートシャップ 新規のpd-1結合ドメイン
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SG10201914027VA (en) 2008-06-27 2020-03-30 Merus Nv Antibody producing non-human mammals
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
AU2013249985B2 (en) * 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
CN110066338B (zh) * 2012-09-27 2024-04-09 美勒斯公司 作为T细胞衔接器的双特异性IgG抗体
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها

Also Published As

Publication number Publication date
BR112020000209A2 (pt) 2020-07-21
KR20200037791A (ko) 2020-04-09
PH12020550011A1 (en) 2020-10-12
IL271817A (en) 2020-02-27
US20240034794A1 (en) 2024-02-01
BR112020000209A8 (pt) 2020-08-11
SG11202000014UA (en) 2020-01-30
AU2018296067A1 (en) 2020-01-30
US11667714B2 (en) 2023-06-06
JP2023171782A (ja) 2023-12-05
WO2019009726A1 (en) 2019-01-10
EP3649154A1 (en) 2020-05-13
TW201920264A (zh) 2019-06-01
US20200325227A1 (en) 2020-10-15
JP7438098B2 (ja) 2024-02-26
CA3068929A1 (en) 2019-01-10
CN111094347A (zh) 2020-05-01
AU2018296067B2 (en) 2021-06-10
JP2020532280A (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
EA202090003A1 (ru) Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
WO2019060917A3 (en) METHODS AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPREADING MODULATORS
CL2019002542A1 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
EA201990578A1 (ru) Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
EA201892312A1 (ru) Триспецифические и/или тривалентные связывающие белки
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
EA201890222A1 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
EA201591467A1 (ru) Анти-lag-3 связывающие белки
ECSP19087580A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
WO2018134235A8 (en) Improved serum albumin binders
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
EA201500818A1 (ru) Антитела к cd47, не вызывающие истощение тромбоцитов и красных кровяных телец, а также способы их применения
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
EA201791918A1 (ru) Модификация белков клеток-хозяев